Because the 3Ms label does not include this item, Government subsidy is often taken for granted. I have been trying to see how we can slip in the "S" (for subsidy) into the 3Ms. But in the end, I still end up with just 3Ms. I suppose the small "s" in the 3Ms could be "subsidy", but in real life our subsidy actually is a big "S" and not a small "s" at all. It is our huge Government subsidy which differentiates our healthcare funding model from that in the US, Japan and many European countries, where hospitals and clinics would charge all their patients at full cost without subsidy. In Singapore, 80% of the patients in our hospitals choose Class B2 or C wards. In these wards, the bulk of the cost is picked up by the Government. For example, a Class C patient going for a hip replacement surgery, which is a major surgery, would cost the hospital, on average, $17,500. Eighty per cent of the cost, or $14,000, is paid by my Ministry through our annual subvention to the hospital. The patient co-pays the remaining 20% or $3,500, which are largely covered by MediShield and his Medisave savings. Mdm Halimah spoke about knee replacement surgery, which she raised last year. We have fixed the problem by revising the claim limits. On average, the cost of treating such a patient in Class C now is about $16,000. My Ministry subsidises about $11,500 with the patient co-paying the remaining $4,500. With Medisave and MediShield, many do not have to pay anything out of pocket, unless they insist on some costly fanciful implants. This is our approach to subsidising care. As medical advances and hospital operating costs go up, we increase our subvention to the hospitals so that patients remain subsidised in accordance with the prescribed subsidy policy. We actually miss the target sometimes. For example, Class B2 subsidy is 65%, with patients co-paying 35% of cost. But, in reality, B2 patients today co-pay 30%, which is five percentage points below target. We will have to close the gap eventually, but let me assure Members that it will be gradual and will not inflict unnecessary hardship on our patients. The idea came from Minister Mentor Lee. Dr Goh Keng Swee sketched out a rough outline. Senior Minister Goh fleshed out the details, persuaded Singaporeans to accept this idea and got it successfully implemented. We have all three to thank for this innovation, which has now become an integral part of Singaporean life. Mdm Halimah asked about the existing Medisave contribution rates. This is tied in with the overall CPF contribution rate and is a factor in employment cost and overall competitiveness. I have no grave concern on the adequacy of the existing Medisave contribution rate. But I must add one caveat on the self-employed who form 12% of CPF members. Many are careful and contribute regularly to their Medisave. They too have an average Medisave balance close to the salaried employees of similar income band. My worry is the 140,000 self-employed members who have an average Medisave balance below $10,000, some just a mere few thousand dollars. Out of this group, only 40% had made some contribution to their Medisave last year. Even then, it is usually just nominally. They would get into problems if they or their dependants fall sick. And it would be worse if they also do not subscribe to MediShield and ElderShield. We must all help to get them into Medisave, MediShield and ElderShield, so that they can enjoy the same protection as the salaried employees. Mdm Halimah asked about the adequacy of the Medisave Minimum Sum. She asked if it is adequate to meet the needs of an ageing population. The current Medisave Minimum Sum is at $32,000 and is not bad for those opting for Class B2 or Class C wards and have MediShield and ElderShield coverage. We will continue to adjust it annually to take into account medical inflation, so as to preserve the purchasing power of the account holders. My concern is that currently, most are not able to achieve the Medisave Minimum Sum by the time they reach 55. The top 40% of income earners are all right, but not those in the lower-income group. That is why we have to be careful in not over-liberalising the use of Medisave for other purposes, which it was not originally designed for. I have the unpleasant task of being the gatekeeper to Medisave. I heard Ms Sylvia Lim. Yes, Medisave is your own money, but if it runs out prematurely, the member will be in trouble. And I am trying to prevent such an outcome. That is why we have stringent Medisave withdrawal rules and limits. This will help to balance current consumption against future needs and ensure that Singaporeans have enough Medisave to look after their medical needs during retirement. Ms Sylvia Lim spoke about the Chronic Disease Management Programme (CDMP) and the deductible of $30 that we put in. She made a couple of observations: one, that the utilisation rate of this scheme seems below expectation, less than 15% of chronically ill have made use of this scheme. It is not a surprise to me because when we estimate the total number of chronically ill, it is based on the disease incidence. Like in all population, probably half of those with chronic illness do not even know they have the disease. And that is why we must step up mass screening. And even among those half who knew they have a chronic disease, not all come forward. Many studies have shown, and again also observed in Singapore, that only half of those who knew they have chronic disease will come forward to see a doctor. And among those who come forward to see a doctor, not all comply; they may decide that changing lifestyle is too troublesome; taking medication is too troublesome, or for whatever reasons. So, when 15% of potential users of this scheme come forward, I thought it was not bad. At first, I thought we cannot even cross 10%. But, yes, we should now aim higher and try to get more people to make use of this scheme. I have spoken to some who are on regular chronic disease management but not using the Medisave. I asked them, they said "why should I", and they gave a couple of reasons. One, some of them are paid for by their employers, so there is no need for them to use their own Medisave. Secondly, some are quite smart, they said that Medisave pays interest rate – I do not know what it is now – 4%-5%. They have enough cash, and they say they will pay cash, which in the bank you cannot even collect 0.5% interest rate today. So, there are all sorts of reasons why we ended up with only 15% utilisation. I do not think we should be discouraged by this figure. The deductible is a problem that can be easily overcome, and I have spoken to GPs and our own polyclinics. And one way they do it – which is quite legitimate and in fact advisable – is they package it up. So, yes, each visit may be only about $30 or $40, as noted by Ms Sylvia Lim. But these are chronic disease management programme, we expect the patients to come forward three or four times a year depending on the risk profile. And, in fact, we want the patients to come forward. We would be very worried if they only come once and disappear. Then compliance would be a problem and their diabetes or high blood pressure will not be managed well. So, many clinics have now offered what is called package deal. They charge per year or even per two years and the whole sum, let us say, $250, will attract the same deductible of $30. The rest can be deducted from their Medisave. So, this is one way to overcome this deductible issue but, more importantly, it secures compliance by the patients.that we consider expanding Medisave for health screening, subject to certain limits and guidelines. I am sympathetic to the call as I believe in prevention. Regular screening and early detection followed by medical intervention and lifestyle changes can avoid future complications and costly medical treatment down the road. There is a case for allowing some Medisave withdrawals for health screening. The question is what kind of health screening? There is a wide range of health screening tests; not all are fully justified or necessary. More screening is not necessarily better. Some accrue benefits more to the provider than the consumer. We must be mindful of such pitfalls. As Dr Fatimah put it, we may be opening a Pandora's Box. A mindless liberalisation of Medisave for health screening may not improve health outcomes, but instead prematurely deplete Medisave balances.